IJE Advance Access published online on February 28, 2005
International Journal of Epidemiology, doi:10.1093/ije/dyh414
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Hormone and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS MSC 7234, Rockville, MD 20852, USA
* To whom correspondence should be addressed. Background Worldwide, breast cancer is the most common cancer and is the leading cause of cancer death among women. Methods To describe global trends, we compared age-adjusted incidence and mortality rates over three decades (from 1973-77 to 1993-97) and across several continents. Results Both breast cancer incidence and mortality rates varied 4-fold by geographic location between countries with the highest and lowest rates. Recent (1993-1997) incidence rates ranged from 27/100 000 in Asian countries to 97/100 000 among US white women. Overall, North American and northern European countries had the highest incidence rates of breast cancer; intermediate levels were reported in Western Europe, Oceania, Scandinavia, and Israel; and Eastern Europe, South and Latin America, and Asia had the lowest levels. Breast cancer incidence rose 30-40% from the 1970s to the 1990s in most countries, with the most marked increases among women aged Conclusions Breast cancer incidence and mortality rates remain highest in developed countries compared with developing countries, as a result of differential use of screening mammograms and disparities in lifestyle and hereditary factors. Future studies assessing the combined contributions of both environmental and hereditary factors may provide explanations for worldwide differences in incidence and mortality rates.
Accepted November 18, 2004
Original paper
Global trends in breast cancer incidence and mortality 1973-1997
2 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852, USA
3 Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852, USA
Louise A. Brinton, E-mail: brintonl{at}mail.nih.gov
Abstract 
50 years. Mortality from breast cancer paralleled incidence: it was highest in the countries with the highest incidence rates (between 17/100 000 and 27/100 000), lowest in Latin America and Asia (7-14/100 000), and rose most rapidly in countries with the lowest rates.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. G Stevens Light-at-night, circadian disruption and breast cancer: assessment of existing evidence Int. J. Epidemiol., August 1, 2009; 38(4): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kim, F. Castro, Y. Paterson, and C. Gravekamp High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action Cancer Res., July 15, 2009; 69(14): 5860 - 5866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xian, L. Pappas, D. Pandya, L. M. Selfors, P. W. Derksen, M. de Bruin, N. S. Gray, J. Jonkers, J. M. Rosen, and J. S. Brugge Fibroblast Growth Factor Receptor 1-Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival Cancer Res., March 15, 2009; 69(6): 2244 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moreno-Aspitia, R. F. Morton, D. W. Hillman, W. L. Lingle, K. M. Rowland Jr, M. Wiesenfeld, P. J. Flynn, T. R. Fitch, and E. A. Perez Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 J. Clin. Oncol., January 1, 2009; 27(1): 11 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hiley, A. Tutt, M. Torres, and C. Palmieri Adjuvant radiotherapy for breast cancer BMJ, December 30, 2008; 337(dec30_1): a2843 - a2843. [Full Text]
|
|
|
|
|
|
S. L. Greenspan, A. Brufsky, B. C. Lembersky, R. Bhattacharya, K. T. Vujevich, S. Perera, S. M. Sereika, and V. G. Vogel Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Oncol., June 1, 2008; 26(16): 2644 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Veselik, S. Divekar, S. Dakshanamurthy, G. B. Storchan, J. M.A. Turner, K. L. Graham, L. Huang, A. Stoica, and M. B. Martin Activation of Estrogen Receptor-{alpha} by the Anion Nitrite Cancer Res., May 15, 2008; 68(10): 3950 - 3958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. Blank, P.-Y. Wong, R. Lakshmanaswamy, R. Guzman, and S. Nandi Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats PNAS, March 4, 2008; 105(9): 3527 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K.T. Tan, L. K. Tan, K. Yu, P. H. Tan, M. Lee, L. H. Sii, C. Y. Wong, G. H. Ho, A. W.Y. Yeo, P. K.H. Chow, et al. Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer Clin. Cancer Res., January 15, 2008; 14(2): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Moral, R. Wang, I. H Russo, C. A Lamartiniere, J. Pereira, and J. Russo Effect of prenatal exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene expression signature J. Endocrinol., January 1, 2008; 196(1): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Waller, S. Moss, J. Watson, and H. Moller The Effect of Mammographic Screening and Hormone Replacement Therapy Use on Breast Cancer Incidence in England and Wales Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2257 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Martin, R. Reiter, M. Johnson, M. S. Shah, M. C. Iann, B. Singh, J. K. Richards, A. Wang, and A. Stoica Effects of Tobacco Smoke Condensate on Estrogen Receptor-{alpha} Gene Expression and Activity Endocrinology, October 1, 2007; 148(10): 4676 - 4686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Matsuno, W. F. Anderson, S. Yamamoto, H. Tsukuma, R. M. Pfeiffer, K. Kobayashi, S. S. Devesa, and P. H. Levine Early- and Late-Onset Breast Cancer Types Among Women in the United States and Japan Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1437 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Chapman, A Murray, J Chakrabarti, A Thorpe, C Woolston, U Sahin, A Barnes, and J Robertson Autoantibodies in breast cancer: their use as an aid to early diagnosis Ann. Onc., May 1, 2007; 18(5): 868 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bergman Jungestrom, L. U. Thompson, and C. Dabrosin Flaxseed and Its Lignans Inhibit Estradiol-Induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts In vivo Clin. Cancer Res., February 1, 2007; 13(3): 1061 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Fawcett and T Blakely Cancer is overtaking cardiovascular disease as the main driver of socioeconomic inequalities in mortality: New Zealand (1981-99) J Epidemiol Community Health, January 1, 2007; 61(1): 59 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Elmore and S. W. Fletcher The Risk of Cancer Risk Prediction: "What Is My Risk of Getting Breast Cancer?" J Natl Cancer Inst, December 6, 2006; 98(23): 1673 - 1675. [Full Text] [PDF]
|
|
|
|
|
|
A. Decarli, S. Calza, G. Masala, C. Specchia, D. Palli, and M. H. Gail Gail Model for Prediction of Absolute Risk of Invasive Breast Cancer: Independent Evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition Cohort J Natl Cancer Inst, December 6, 2006; 98(23): 1686 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, A. Gompel, and P. Forgez Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression. Cancer Res., June 15, 2006; 66(12): 6243 - 6249. [Abstract] [Full Text] [PDF]
|
|